Back to Search Start Over

Patient journey in gastroesophageal reflux disease: real-world perspectives from Italian gastroenterologists, primary care physicians, and ENT specialists.

Authors :
Pasta A
Pelizzaro F
Marabotto E
Calabrese F
Formisano E
Djahandideh Sheijani S
Brandimarte G
Manes G
Gravina AG
Savarino EV
Source :
Therapeutic advances in gastroenterology [Therap Adv Gastroenterol] 2024 Mar 22; Vol. 17, pp. 17562848241239590. Date of Electronic Publication: 2024 Mar 22 (Print Publication: 2024).
Publication Year :
2024

Abstract

Background: Gastroesophageal reflux disease (GERD) is a challenging condition that involves different physicians, such as general practitioners (GPs), gastroenterologists, and ears, nose and throat (ENT) specialists. A common approach consists of proton-pump inhibitors (PPIs) administration. Adjunctive pharmacological treatment may have a role in the management of non-responders to PPIs.<br />Objectives: We aimed to survey GPs and different medical specialists to investigate the medical approaches to patients reporting GERD symptoms. In addition, we examined the use of adjunctive pharmacological treatments in patients with GERD symptoms who do not respond to PPIs.<br />Design: Retrospective observational study.<br />Methods: A survey was conducted among a large sample of gastroenterologists, GPs, and ENT specialists. Symptoms were divided into typical and extraesophageal, and their severity and impact on quality of life were explored with the GERD Impact Scale and with Reflux Symptom Index (RSI). All therapies administered usually for GERD were investigated.<br />Results: A total of 6211 patients were analyzed in this survey. Patients with typical symptoms were 53.5%, while those with extraesophageal symptoms were 46.5%. The latter were more frequently reported by ENT patients (53.6%, p  < 0.0001). The GSI was higher in patients followed by gastroenterologists (9 points) and GPs (9 points) than ENT specialists (8 points), but the RSI was higher in the ENT group (14.3 ± 6.93) than in GPs and gastroenterologist groups (10.36 ± 6.36 and 10.81 ± 7.30, p  < 0.0001). Chest pain had the highest negative impact on quality of life ( p  < 0.0001). Of the 3025 patients who used PPIs, non-responders showed a lower GSI when treated with a combination of adjunctive pharmacological treatments and bioadhesive compounds, than with single-component drugs.<br />Conclusion: Patients with GERD referred to a gastroenterologist had more severe disease and poorer quality of life. The combination of adjunctive pharmacological treatments and bioadhesive compounds seems to be effective in the management of PPI refractory patients.<br /> (© The Author(s), 2024.)

Details

Language :
English
ISSN :
1756-283X
Volume :
17
Database :
MEDLINE
Journal :
Therapeutic advances in gastroenterology
Publication Type :
Academic Journal
Accession number :
38524789
Full Text :
https://doi.org/10.1177/17562848241239590